Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

计划入组 29 人 · 首次发布于 2013 年 7 月 9 日

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

计划入组 12 人 · 首次发布于 2024 年 7 月 16 日

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

计划入组 4 人 · 首次发布于 2019 年 5 月 21 日

Cedazuridine(Inqovi 5 Tablet Pack, Inaqovi)

C₉H₁₄F₂N₂O₅

agenT-842

agenT 04002

HEC Pharm USA Inc.

United States

Zhejiang Starry Pharmaceutical Co., Ltd.

China

Allup Silica Ltd

Canada

Ipilimumab and Nivolumab Show Promise in Higher-Risk Myelodysplastic Syndromes

PureTech's LYT-200 Shows Promising Results in Phase 1b Trial for Relapsed/Refractory Blood Cancers

Taiho Oncology Announces Publication of Final Results from ASCERTAIN Clinical Trial